Full Fed. Circ. Won't Review Nixing Of Apotex Patent
Apotex Inc. struck out Tuesday in its bid to have the full Federal Circuit review its decision to invalidate a high blood pressure drug patent, with the court not moved by...To view the full article, register now.
Already a subscriber? Click here to view full article